Rayan Mubarak is Co-Founder of Enjamb Labs, a full-stack AI agent platform accelerating Biopharma R&D, and a Y Combinator P26 company based in San Francisco.

Rayan is an ML and neuroscience researcher who conducted research across five academic labs at the University of Florida and Florida International University, focusing on developing therapeutics for pesticide poisoning.

Rayan has published first-authored papers and presented at premier conferences including the Society of Toxicology (SOT) and the International Society for Computational Biology (ISCB), and built DeepImmunoGene, an ML framework that outperforms state-of-the-art lung cancer immunotherapy biomarker detection by 20%.

At Enjamb Labs, Rayan co-leads the development of a single agentic workspace that unifies clinical evidence synthesis, regulatory document drafting, and statistical programming to cut months off the drug development timeline. He has also been invited to speak at Northeastern University's Silicon Valley campus on founding and scaling an AI startup through Y Combinator.

Enjamb's platform addresses a $2.6 billion, 10-plus year drug development process by deploying AI agents across the entire drug program from preclinical research through clinical trials and FDA approval, with integrations across 66 scientific databases and 50-plus fine-tuned models.